ObjectiveResection is the treatment of choice for patients with stage I non–small cell lung cancer. Stage I non–small cell lung cancer has been further subdivided into IA (T1N0M0, tumor size ≤ 3 cm without visceral pleural invasion) and IB (T2N0M0, tumor size > 3 cm or any size with visceral pleural invasion). The aim of this study was to evaluate the prognostic factors in patients with resected stage I non–small cell lung cancer with a diameter of 3 cm or less.MethodsWe retrospectively reviewed the clinicopathologic characteristics of 445 patients with resected stage I non–small cell lung cancer with a diameter of 3 cm or less who were treated at Taipei Veterans General Hospital between 1980 and 2000. Disease-free survival, overall surviva...
ObjectiveWith the widespread use of computed tomography and the emergence of screening programs, non...
BackgroundThe goal of this study was to investigate the prognostic factors and patterns of recurrenc...
BackgroundIncreased tumor size is a known risk for poor outcomes in patients with stage I and II non...
ABSTRACT: Significant heterogenity of stage IB (sixth edition of the TNM staging system) nonsmall ce...
BackgroundThe T2 descriptor for staging non-small cell lung cancer (NSCLC) contains several non-size...
BackgroundThe T2 descriptor for staging non-small cell lung cancer (NSCLC) contains several non-size...
The current TNM staging system for non-small cell lung cancer subdivides stage IA and IB according t...
BackgroundThe purpose of this study was to identify risk factors for disease recurrence and unfavora...
The current TNM staging system for non-small cell lung cancer subdivides stage IA and IB according t...
AbstractObjective: Among the TNM criteria, tumor size is a well-assessed factor in the prognosis of ...
Background and objective The new edition of the TNM staging for lung and pleural tumours has been fi...
BackgroundThe objective of this retrospective study was to identify prognostic factors in completely...
ObjectivesOur objective was to identify surgical–pathologic factors affecting prognosis in stage IB ...
Background: Visceral pleural invasion (VPI) is an adverse prognostic factor in non-small cell lung c...
ObjectivesOur objective was to identify surgical–pathologic factors affecting prognosis in stage IB ...
ObjectiveWith the widespread use of computed tomography and the emergence of screening programs, non...
BackgroundThe goal of this study was to investigate the prognostic factors and patterns of recurrenc...
BackgroundIncreased tumor size is a known risk for poor outcomes in patients with stage I and II non...
ABSTRACT: Significant heterogenity of stage IB (sixth edition of the TNM staging system) nonsmall ce...
BackgroundThe T2 descriptor for staging non-small cell lung cancer (NSCLC) contains several non-size...
BackgroundThe T2 descriptor for staging non-small cell lung cancer (NSCLC) contains several non-size...
The current TNM staging system for non-small cell lung cancer subdivides stage IA and IB according t...
BackgroundThe purpose of this study was to identify risk factors for disease recurrence and unfavora...
The current TNM staging system for non-small cell lung cancer subdivides stage IA and IB according t...
AbstractObjective: Among the TNM criteria, tumor size is a well-assessed factor in the prognosis of ...
Background and objective The new edition of the TNM staging for lung and pleural tumours has been fi...
BackgroundThe objective of this retrospective study was to identify prognostic factors in completely...
ObjectivesOur objective was to identify surgical–pathologic factors affecting prognosis in stage IB ...
Background: Visceral pleural invasion (VPI) is an adverse prognostic factor in non-small cell lung c...
ObjectivesOur objective was to identify surgical–pathologic factors affecting prognosis in stage IB ...
ObjectiveWith the widespread use of computed tomography and the emergence of screening programs, non...
BackgroundThe goal of this study was to investigate the prognostic factors and patterns of recurrenc...
BackgroundIncreased tumor size is a known risk for poor outcomes in patients with stage I and II non...